1. In Vivo
  2. >>Business Strategy

Driving Change In Health Care

Jhaymee Tynan Talks About Patient Care In 2020 And Promoting Diversity

 
• By Maire Gerrard

Jhaymee Tynan, assistant vice president of integration at Atrium Health and creator and founder of the 100x2030 Initiative, speaks to In Vivo about her journey into health care, putting the patient first, and the importance of encouraging diversity in the industry.

IV2008_Diversity-And-Healthcare_1200
'Diversity and inclusion will become part of how we do business and will be the foundation for how we move forward' • Source: Shutterstock

Jhaymee Tynan, one of In Vivo’s 2020 Rising Leaders, did not initially pursue a career in health care. After graduating from Virginia Tech with a bachelor’s degree in finance, insurance and business law, she aspired to work in banking. However, Tynan realized that while she enjoyed elements of the work, it did not offer her what she was looking for long-term. “I enjoyed working with people and solving problems, but I wanted a different lifestyle and work-life balance, and also wanted to be able to make an impact on people,” Tynan recalled in an exclusive interview.

At the same time, Tynan’s mother was dealing with health issues, and one particular visit spurred her to consider a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Infographic: How Big Pharma Is Scaling Beyond Pilot AI Projects

 
• By David Wild

Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.

When VC Steps Back: Finding Alternative Biotech Funding

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 
• By Anabel Costa-Ferreira

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

More from In Vivo

video
Sponsored by:

Meeting the demands of the global biologics market

Lonza is addressing the growing global demand for biologics by utilizing its expert teams and the advanced capabilities of its newly acquired large-scale manufacturing site in Vacaville, California. Joanna McCafferty, Director of Commercial Development, shares more in this brief video. Ask ChatG

Mapping The Power And Potential Of Europe’s Market Access Collaborations

 
• By Leela Barham

Understand who’s influencing access decisions and how pharma can engage strategically across the continent.

Infographic: How Big Pharma Is Scaling Beyond Pilot AI Projects

 
• By David Wild

Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.